Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $30,600.00 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the sale, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This represents a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Denali Therapeutics Stock Down 4.0 %

Shares of NASDAQ:DNLI opened at $28.45 on Friday. The business’s 50 day moving average is $28.20 and its 200 day moving average is $23.91. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the firm earned ($0.72) EPS. Analysts forecast that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DNLI has been the subject of several recent analyst reports. Wedbush reduced their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Bank of America raised their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Jefferies Financial Group upped their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. MONECO Advisors LLC grew its holdings in shares of Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after acquiring an additional 400 shares in the last quarter. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares during the last quarter. CWM LLC grew its stake in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Denali Therapeutics by 5.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after purchasing an additional 1,372 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.